Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Summary

The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.

Conditions

• End Stage Liver Disease
• Hepatitis C

Interventions

DRUG

Daclizumub

anti-rejection drug

DRUG

Tacrolimus

anti rejection drug

DRUG

Cyclosporine

anti rejection drug

DRUG

MMF

anti rejection drug

Sponsors & Collaborators

• Baylor Health Care System

  collaborator OTHER

• Emory University

  collaborator OTHER

• University of Southern California

  collaborator OTHER

• Mayo Clinic - Scottsdale/Phoenix, Arizona

  collaborator UNKNOWN

• New York Presbyterian Hospital

  collaborator OTHER

• Oregon Health and Science University

  collaborator OTHER

• New York University

  collaborator OTHER

• University of Cincinnati

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• The University of Texas Health Science Center at San Antonio

  collaborator OTHER

• University of Chicago

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• Mayo Clinic - Rochester, Minnesota

  collaborator UNKNOWN

• Medical University of South Carolina

  collaborator OTHER

• University of Virginia

  collaborator OTHER

• Lahey Clinic

  collaborator OTHER

• University of Medicine and Dentistry of New Jersey

  collaborator OTHER

• Northwestern Memorial Hospital

  collaborator OTHER

• Baylor Research Institute

  lead OTHER

Principal Investigators

• Goran Klintmalm, MD · Baylor Univeristy Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2002-07-31

Primary Completion

2006-04-30

Completion

2007-01-31

Countries

• United States

Study Locations